Updated therapeutic approach in the management of Polycystic Ovary Syndrome (PCOS): A Review
DOI:
https://doi.org/10.21276/IJRDPL.2278-0238.2019.8(2).37-42Keywords:
Polycystic ovary syndrome, metabolic disorder, ContraceptivesAbstract
Polycystic ovary syndrome (PCOS) is a heterogeneous clinical entity that is defined as the association of hyperandrogenism with chronic an ovulation in women without specific underlying diseases of the adrenal or pituitary glands. PCOS is also associated with a metabolic disturbance with complex inter relation of obesity, insulin resistance and endocrine abnormalities remains unresolved. However, several studies link obesity, body fat distribution and nutritional habits with the hormonal and metabolic profiles of PCOS. Moreover, intervention studies have suggested that reducing weight and hyper insulinaemia either by diet alone or by a combination of diet with drugs improves hirsutism, fertility, hormonal and metabolic profiles of PCOS. In fact, the evaluation of nutritional factors in PCOS is helpful for the screening of metabolic abnormalities and the management of women with PCOS. A point of particular interest in the management of PCOS is that the choice of contraception remains difficult in these high cardiovascular risk women. The lack of prospective studies to evaluate long-term metabolic and cardiovascular tolerance necessitates care and the assessment of other hormonal possibilities
Downloads
References
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med.2005; 352: 1223–1236.
Lauritsen MP, Bentzen JG, Pinborg A. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014; 29: 791–801.
Carmina E & Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897–1899.
Biyasheva A., Richard S. Legro, Margritd U. Evidence for association between PCOS and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2. J Clin Endocrinol Medtab 2009; 94(7): 2495–2501.
Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brink Worth GD. The effect of weight loss on anti-mullerian hormone levels in over weight and obese women with polycyctic ovary syndrome and reproductive impairment, reproductive. Endocrinology 2009; (24): 1976-1981.
Londe P, and Agarwal S. Invitro phytochemical study on Berberis aristataroot extracts: An effective neutraceutical for the treatment of polycystic ovarian syndrome. International Journal of Recent Scientific Research.2017; 8(9): 19934-19940.
Bency Baby T, Smitha Rani, Remya K, Shebina PR, Azeem AK. Polycystic ovarian syndrome: Therapeutic potential of herbal remedies-A review. International Journal of herbal Medicine 2016; 4(5): 91-96.
Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries-a common finding in normal women. Lancet. 1988; 1: 870-2.
Abdel Gadir A, Khatim MS, Mowafi RA, Alnaser HM, Muharib NS, Shaw RW. Implications of ultrasonically diagnosed polycystic ovaries. I. Correlationwith basal hormonal profiles. Hum Reprod 1992; 7: 453-457.
Grey S. Genital System Disorders. Pediatrics in Review 2013; 3: 11.
Sultan C, Paris F. Clinical Expression of polycyctic ovary syndrome in adolescent girls. Fertil Steril. 2006; 86 (Suppl 1): S6.
Soni NR. Current Management on PCOS (polycystic ovary syndrome)/Stein Leventhal Syndrome. Investigation in gynecology research and women health 2017; 1(3): 1-3.
Gupta S, Das A, Reddy B M. Present status of understanding the etiology of PCOS. Journal of Postgraduate medicine, 2008; 54(2): 115-125.
Norman RJ, Hagne WM, Masters SC, Wang XJ. Subjects with polycystic ovary without a hyperandrogenism exhibit similar disturbances in insulin and lipid profile as those with polycystic ovary syndrome. Hum Repord 1995; 10: 2258-2262.
Gambineri A, Pelusi C, Vicennati V, Pagatto U, Pasquali R. Obesity and polycystic ovary syndrome. Int j obestet, 2002; 26: 83-896.
Dimanti-kandarakis E, Piperi C, Spina J. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones 2006; 5 (1): 17-34.
Balen A. Polycystic ovary syndrome and cancer. Hum reprod update 2001; 7: 522-525.
Petraglia F, Luisi S, Leo VD, Musacchio C. Hormone- dependent gynaecological disorders: a pathophysiological perspective for appropriate treatment. Best Pract Res Clin Obstet Gynaecol 2008; (22): 237
Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab 2006; 31:384-391
Douglas CC, Gower BA, Darnell BE. Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril 2006; 85: 679-688.
American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion No. 448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol. 2009; 114(6): 1428–1431.
Kahn JA, Gordon CM. Polycystic ovary syndrome. AdolescMed.1999; 10: 321–336.
Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother. 2002; 3: 1177–1189.
Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE, A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab. 2000; 88: 1927–1932.
Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs.2004; 64: 2447–2462.
Bruni V, Dei M, Pontello V, Vangelisti P. The management of polycystic ovary syndrome. Ann N Y Acad Sci.2003; 997: 307–321.
Cakmak H, Rosen MP. Current Clinical Approaches to Protecting the Ovary. Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity. Publish by Academic Press, 2015
Pritts EA. Treatment of the infertile patient with polycystic ovarian syndrome. Obstet Gynecol Surv, 2002; 57: 587–597.
Pelusi C, Pasquali R: Polycystic ovary syndrome in adolescents. Pathophysiology and treatment implications. Treat Endocrinol. 2003; 2: 215–230.
Rittmaster RS. Antiandrogen treatment of polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America 1999; 28 (2): 409-421.
Carroll N, Palmer JR. A comparison of intrauterine versus intra cervical insemination in fertile single women. Fertil Steril. 2001; 75(4): 656–660.
Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulinsensitivity but persistently increased early insulin secretion afterweight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab1995; 80: 2586–2593.
Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemiain the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988; 50: 197–212.
Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812–819.
Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470–1474.
How to cite this article:
Kaul A, Zar N, Shangloo S and Nain N. Updated therapeutic approach in the management of Polycystic Ovary Syndrome (PCOS): A Review. Int. J. Res. Dev. Pharm. L. Sci. 2019; 8(2): 37-42. doi: 10.13040/IJRDPL.2278-0238.8(2).37-42
This Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
.